Eupraxia Pharmaceuticals has released sub-score data from its ongoing Phase 1b/2a RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (EoE), a disease affecting more than 450,000 people in the United States. The data were presented at the Digestive Disease Week conference in Chicago and demonstrate improvements in both tissue inflammation and fibrosis in patient cohorts.
The EoEHSS (EoE Histology Scoring System) is a standardized method used to monitor esophageal tissue damage in EoE patients. It comprises eight individual features: four evaluating inflammation and four evaluating architectural and fibrotic aspects of the disease. In the Phase 1b/2a portion of the RESOLVE trial, EoEHSS data were measured at baseline, week 4, week 12, and for patients in Cohorts 5-9 at week 36.
EoEHSS sub-scores for inflammation demonstrated improvements in all reported cohorts at both 12 weeks with 31 patients and 36 weeks with 27 patients. For the inflammation sub-score, improvements in both grade and stage were seen across all cohorts at week 12 and week 36. EoEHSS sub-scores for tissue architecture, which measures fibrosis, demonstrated improvements across most reported cohorts at 12 and 36 weeks. The largest improvements in both sub-scores at weeks 12 and 36 were observed in the highest dose cohort, where the improvement in inflammation grade and stage was greater than 90 percent at both time points, and the improvement in architecture grade and stage was greater than 83 percent.
The RESOLVE trial is a multicenter, open-label, dose-escalation study of EP-104GI in adults with active EoE. Treatment is administered as a single dose via 4 to 20 esophageal wall injections. The Phase 2b randomized, placebo-controlled portion of the RESOLVE trial is currently recruiting with top-line data expected in Q4 2026. EoE is an inflammatory disease in which white blood cells migrate into the esophagus, creating pain and difficulty with swallowing food, with symptoms frequently leading to mental health issues.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.globenewswire.com/news-release/2026/05/06/3288658/0/en/Eupraxia-Pharmaceuticals-First-Release-of-EoEHSS-Sub-Scores-Data-from-its-Ongoing-Phase-1b-2a-RESOLVE-Trial-in-Eosinophilic-Esophagitis-at-Digestive-Disease-Week.html